Literature DB >> 21198834

Multiplicative rating scales do not enable measurement of vision-related quality of life.

Vijaya K Gothwal1, Thomas A Wright, Ecosse L Lamoureux, Konrad Pesudovs.   

Abstract

PURPOSE: Many questionnaires for the measurement of visual impairment exist. One, the Houston Vision Assessment Test (HVAT), takes a different approach: the patient is asked to rate overall impairment and the proportion attributed to vision, then through multiplication the visual and non-visual (physical) impairments are calculated. The purpose of this study was to determine whether the scores derived from this approach can be considered to be measures.
METHODS: The participants were 193 cataract patients awaiting surgery (mean age 74.1 ± 9.8 years, 54 per cent female and 53.6 per cent were awaiting first eye surgery), who self-administered the HVAT, which consists of 10 questions, whereby impairment on each activity and the proportion attributable to vision is rated. Therefore, total, visual and physical impairments are calculated. For each question, multiplying the impairment (five response categories) by the proportion due to eyesight (five categories) gives 10 possible levels of visual impairment. Assessment of the multiplicative rating scales included frequency of category use and hierarchical ordering of response categories using category thresholds. Summary statistics of Rasch analysis were generated for the rating scale and overall questionnaire performance.
RESULTS: In the multiplicative scale, higher response categories were under-utilised and thresholds were disordered, indicating that the categories did not function as intended. Some of the dysfunction arose from disordered thresholds in the 'proportion due to eyesight scale', but repairing this gave little improvement to the multiplicative scale. The ill-defined nature of the disordered categories precluded further repair by combining categories. Measurement precision, as indicated by person separation reliability, was poor (0.70).
CONCLUSION: Rasch analysis demonstrated that the categories of the multiplied rating scale of the HVAT were not ordered, as the user would expect; this precludes measurement. This provides evidence against the use of multiplicative rating scales in quality-of-life questionnaires. It would be better to use a single rating scale for each construct of interest.
© 2010 The Authors. Clinical and Experimental Optometry © 2010 Optometrists Association Australia.

Entities:  

Mesh:

Year:  2011        PMID: 21198834     DOI: 10.1111/j.1444-0938.2010.00554.x

Source DB:  PubMed          Journal:  Clin Exp Optom        ISSN: 0816-4622            Impact factor:   2.742


  5 in total

1.  The impact of diabetic retinopathy on quality of life: qualitative findings from an item bank development project.

Authors:  Eva K Fenwick; Konrad Pesudovs; Jyoti Khadka; Mohamed Dirani; Gwyn Rees; Tien Y Wong; Ecosse L Lamoureux
Journal:  Qual Life Res       Date:  2012-12       Impact factor: 4.147

2.  Reliability, validity and responsiveness of the Greek MacDQoL individualized measure of the impact of macular degeneration on quality of life.

Authors:  Theodoros P Marakis; Chrysanthi Koutsandrea; Klio I Chatzistefanou; Yannis Tountas
Journal:  Qual Life Res       Date:  2016-09-10       Impact factor: 4.147

3.  Evaluation of item candidates for a diabetic retinopathy quality of life item bank.

Authors:  Eva K Fenwick; Konrad Pesudovs; Jyoti Khadka; Gwyn Rees; Tien Y Wong; Ecosse L Lamoureux
Journal:  Qual Life Res       Date:  2012-11-08       Impact factor: 4.147

4.  Development of the Vision Impairment in Low Luminance Questionnaire.

Authors:  Susanne G Pondorfer; Jan H Terheyden; Helen Overhoff; Jana Stasch-Bouws; Frank G Holz; Robert P Finger
Journal:  Transl Vis Sci Technol       Date:  2021-01-06       Impact factor: 3.283

5.  The importance of rating scales in measuring patient-reported outcomes.

Authors:  Jyoti Khadka; Vijaya K Gothwal; Colm McAlinden; Ecosse L Lamoureux; Konrad Pesudovs
Journal:  Health Qual Life Outcomes       Date:  2012-07-13       Impact factor: 3.186

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.